Orthocell Ltd Asset Resilience Ratio

Latest as of June 2025: 81.22%

Orthocell Ltd asset resilience ratio. Orthocell Ltd (OCC) has an Asset Resilience Ratio of 81.22% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See OCC defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

AU$28.62 Million
≈ $20.25 Million USD Cash + Short-term Investments

Total Assets

AU$35.24 Million
≈ $24.93 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Orthocell Ltd (2017–2025)

Asset resilience ratio of Orthocell Ltd from 2017 to 2025. This chart shows how Orthocell Ltd's Asset Resilience Ratio has changed over time. Read OCC liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Orthocell Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Orthocell Ltd asset portfolio.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$28.62 Million 81.22%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$28.62 Million 81.22%

Asset Resilience Insights

  • Very High Liquidity: Orthocell Ltd maintains exceptional liquid asset reserves at 81.22% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Orthocell Ltd Industry Peers by Asset Resilience Ratio

Compare Orthocell Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
Biotechnology 35.16%
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294
Biotechnology 23.15%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
Achieve Life Sciences Inc
F:SP4P
Biotechnology 3.60%

Orthocell Ltd Asset Resilience Ratio by Year (2017–2025)

Orthocell Ltd asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Orthocell Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 75.20% AU$26.50 Million
≈ $18.75 Million
AU$35.24 Million
≈ $24.93 Million
-2.25pp
2024-06-30 77.45% AU$20.61 Million
≈ $14.59 Million
AU$26.62 Million
≈ $18.83 Million
-6.38pp
2023-06-30 83.83% AU$24.82 Million
≈ $17.56 Million
AU$29.61 Million
≈ $20.95 Million
+54.75pp
2022-06-30 29.08% AU$11.02 Million
≈ $7.80 Million
AU$37.90 Million
≈ $26.81 Million
-55.39pp
2021-06-30 84.47% AU$16.33 Million
≈ $11.55 Million
AU$19.33 Million
≈ $13.68 Million
-3.75pp
2020-06-30 88.22% AU$20.44 Million
≈ $14.46 Million
AU$23.17 Million
≈ $16.39 Million
+5.59pp
2019-06-30 82.63% AU$11.24 Million
≈ $7.95 Million
AU$13.60 Million
≈ $9.62 Million
+26.99pp
2018-06-30 55.65% AU$2.91 Million
≈ $2.06 Million
AU$5.23 Million
≈ $3.70 Million
-14.84pp
2017-06-30 70.49% AU$5.05 Million
≈ $3.57 Million
AU$7.16 Million
≈ $5.07 Million
--
pp = percentage points

About Orthocell Ltd

AU:OCC Australia Biotechnology
Market Cap
$109.42 Million
AU$154.65 Million AUD
Market Cap Rank
#18673 Global
#576 in Australia
Share Price
AU$0.57
Change (1 day)
+3.64%
52-Week Range
AU$0.50 - AU$1.16
All Time High
AU$1.75
About

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membr… Read more